NCT05395429 is a clinical trial in Thyroid Cancer, sponsored by Genetron Health.

Who is sponsoring NCT05395429?

NCT05395429 is sponsored by Genetron Health.

What condition does NCT05395429 study?

NCT05395429 studies Thyroid Cancer.

Is NCT05395429 still recruiting?

NCT05395429 is currently status unknown. Last updated 23 February 2023.

Last reviewed 2023-02-23 · How we verify

NCT05395429

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients

Status unknown Last updated 23 February 2023

What this trial tests

trial in Thyroid Cancer in 1,000 participants. Status unknown.

Timeline

25 March 2022

Primary endpoint
15 November 2023

15 December 2023

Quick facts

Lead sponsor	Genetron Health
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	25 March 2022
Primary completion	15 November 2023
Estimated completion	15 December 2023
Sites	4 locations across China

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →

Sponsor

Genetron Health

Who can join

Eligibility, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trail is to evaluate the performance of Genetron TERT/BRAF PCR Kit in Thyriod Cancer patients using real-time PCR method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Genetron Health trials

Trials by the same sponsor.

NCT05494853 — Novel Biomarker Assay for Biomarker Assay for HCC Detection · unknown
NCT05343832 — Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients · unknown
NCT05400018 — Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients · completed
NCT05023746 — Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients · completed
NCT05100602 — Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05395429 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genetron Health
Last refreshed: 23 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05395429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing